Clinical Trial

First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 15, 2024 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a phase 1, first-in-human, open-label, dose-escalation and dose-expansion study designed to evaluate the safety and tolerability, pharmacokinetics characteristics and preliminary anti-tumor activity of LPM6690176 capsules in patients with advanced solid tumors.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-26; most recent amendment 2024-03-12.
Status change: Not Yet Recruiting → Recruiting 2024-03-12
Trial Details
NCT Number NCT06240546
Lead Sponsor Luye Pharma Group Ltd.
Conditions Advanced Solid Tumor
Enrollment 102 participants
Start Date 2024-03-12
Primary Completion 2026-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2024-03-15